785-56-8

Basic information

• Product Name: 3,5-Bis(trifluoromethyl)benzoyl chloride
• Synonyms: 3,5-Bis(trifluoromethyl)benzoylchloride98%;3,5-BIS(TRIFLUOROMETHYL)BENZOYCHLORIDE;Benzoyl chloride, 3,5-bis(trifluoromethyl)-;3,5-Bis(trifluoromethyl)benzoic acid chloride;3,5-Bis(trifluoromethyl)benzoyl chloride,97%;Benzoyl Chloride, 3;3,5-bis(Trifluoromethyl)benzoyl chloride, 95+%;[3,5-bis(trifluoroMethyl)phenyl]carbonylchloranuide
• CAS NO: 785-56-8
• Molecular Formula: C₉H₃ClF₆O
• Molecular Weight: 276.56
• EINECS: 212-322-0
• Product Categories: Miscellaneous;Benzotrifluoride Series;Acid Halides;Carbonyl Compounds;Organic Building Blocks
• Mol File: 785-56-8.mol
• Article Data: 24

Chemical Properties

• Melting Point: 5-10C
• Boiling Point: 65-67 °C (12 mmHg)
• Flash Point: 162 °F
• Appearance: Clear colorless to very slightly yellow/Liquid
• Density: 1.526 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0865mmHg at 25°C
• Refractive Index: n20/D 1.435(lit.)
• Sensitive: Moisture Sensitive
• BRN: 2593440
• CAS DataBase Reference: 3,5-Bis(trifluoromethyl)benzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Bis(trifluoromethyl)benzoyl chloride(785-56-8)
• EPA Substance Registry System: 3,5-Bis(trifluoromethyl)benzoyl chloride(785-56-8)

Safety Data

• Hazard Codes: C
• Statements: 34-37-36
• Safety Statements: 26-36/37/39-45-27
• RIDADR: UN 3265 8/PG 2
• WGK Germany: 3
• F: 10-19-21
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 785-56-8(Hazardous Substances Data)

Usage

Chemical Properties

clear colorless to very slightly yellow liquid

Uses

3,5-Bis(trifluoromethyl)benzoyl chloride was used in the quantitative and selective assay for the measurement of low levels of clonidine in human plasma.

InChI:InChI=1/C10H4Cl3F17Si/c11-31(12,13)2-1-3(14,15)4(16,17)5(18,19)6(20,21)7(22,23)8(24,25)9(26,27)10(28,29)30/h1-2H2

Upstream product

• 725-89-3 3,5-bistrifluoromethylbenzoic acid 
• 402-31-3 1,3-bis(trifluoromethyl)benzene 
• 328-70-1 3,6-bis(trifluoromethyl)bromobenzene 
• 401-96-7 3,5-bis(trifluoromethyl)benzoyl fluoride 
• 1026194-04-6 N-(5-amino-2-methylphenyl)-5-(3-pyridyl)-2-pyrimidinamine 

Downstream Products

• 30071-93-3 3,5-bis(trifluoromethyl)phenyl methyl ketone 
• 863-99-0 Di-<3.5-bis-trifluormethyl-benzoyl>-peroxyd 
• 20929-20-8 3,5-Di-(trifluormethyl)-benzoesaeure-N-methyl-N-<2-dimethylamino-ethyl>-amid 
• 202822-34-2 N-(5-chloro-2-methoxyphenyl)-3,5-bis(trifluoromethyl)benzamide 
• 690663-30-0 methyl 3,5-bistrifluoromethylbenzohydroxamate 
• 346608-02-4 3,5-bis(trifluoromethyl)benzoic acid 2-pyridinylmethyl ester 
• 681291-90-7 C₂₃H₂₁F₆NO₃ 
• 167262-74-0 1-[3,5-bis-(trifluoromethyl)-benzoyl]-3-(3,4-dichloro-phenyl)-3-(2-hydroxy-ethyl)-pyrrolidine 

Relevant articles and documents

Cyano-and ketone-containing selenoesters as multi-target compounds against resistant cancers

Fifteen selenocompounds, comprising of eight ketone-containing selenoesters (K1–K8, also known as oxoselenoesters) and seven cyano-containing selenoesters (N1–N7, known also as cyanoselenoesters), have been designed, synthesized, and evaluated as novel anticancer agents. These compounds are derivatives of previously reported active selenoesters and were prepared following a three-step one-pot synthetic route. The following evaluations were performed in their biological assessment: cytotoxicity determination, selectivity towards cancer cells in respect to non-cancer cells, checkerboard combination assay, ABCB1 inhibition and inhibition of ABCB1 ATPase activity, apoptosis induction, and wound healing assay. As key results, all the compounds showed cytotoxicity against cancer cells at low micromolar concentrations, with cyanoselenoesters being strongly selective. All of the oxoselenoesters, except K4, were potent ABCB1 inhibitors, and two of them, namely K5 and K6, enhanced the activity of doxorubicin in a synergistic manner. The majority of these ketone derivatives modulated the ATPase activity, showed wound healing activity, and induced apoptosis, with K3 being the most potent, with a potency close to that of the reference compound. To summarize, these novel derivatives have promising multi-target activity, and are worthy to be studied more in-depth in future works to gain a greater understanding of their potential applications against cancer.

Isoalantolactone derivative, pharmaceutical composition and application thereof

The invention relates to an isoalantolactone derivative, a pharmaceutical composition and application thereof, especially use of the isoalantolactone derivative shown as formula (I) or a salt pharmaceutical compound thereof in preparation of adjuvant drugs treating cancer, a pharmaceutical composition containing a therapeutically effective amount of isoalantolactone derivative (I) or its salt anda pharmaceutically acceptable carrier or a composition with other anticancer drugs.

Production method of fluvoxamine maleate intermediate (5-methoxy-1-(4-trifluoromethyl benzyl)pentanone)

The invention provides a production method of a fluvoxamine maleate intermediate (5-methoxy-1-(4-trifluoromethyl benzyl)pentanone). The production method comprises the following steps of adding 1,2-dichloroethane into 3,5-difluoromethyl benzoic acid, mixing under the low-temperature environment, heating to 60 to 65 DEG C, uniformly stirring, continuing to heat to 80 to 90 DEG C, dripping thionyl chloride, heating and refluxing, stirring to react until no gas overflows, reducing pressure, and distilling, so as to obtain 3,5-bis(trifluoromethyl) benzoyl chloride; adding 1-bromo-4-methyl butyl ether into a solvent, uniformly mixing, adding carbon nanotube-modified magnesium micro-nanoparticle to mix, and dripping benzene diiodide, so as to obtain a Grignard reagent containing the carbon nanotubes; under the ice bath environment, adding the 3,5-bis(trifluoromethyl) benzoyl chloride into a solvent, adding a ferrous chloride catalyst to mix, adding the Grignard reagent containing the carbonnanotubes, and continuing to react, so as to obtain the 5-methoxy-1-(4-trifluoromethyl benzyl)pentanone.